Literature DB >> 17965547

Free radical scavenger edaravone suppresses x-ray-induced apoptosis through p53 inhibition in MOLT-4 cells.

Nakashi Sasano1, Atsushi Enomoto, Yoshio Hosoi, Yosuke Katsumura, Yoshihisa Matsumoto, Kenshiro Shiraishi, Kiyoshi Miyagawa, Hiroshi Igaki, Keiichi Nakagawa.   

Abstract

Edaravone, a clinical drug used widely for the treatment of acute cerebral infarction, is reported to scavenge free radicals. In the present study, we investigated the radioprotective effect of edaravone on X-ray-induced apoptosis in MOLT-4 cells. Apoptosis was determined by the dye exclusion test, Annexin V binding assay, cleavage of caspase, and DNA fragmentation. We found that edaravone significantly suppressed the X-ray-induced apoptosis. The amount of intracellular ROS production was determined by the chloromethyl-2',7'-dichlorodihydro-fluorescein diacetate system. We found that the intracellular ROS production by X-irradiation was completely suppressed by the addition of edaravone. The accumulation and phosphorylation of p53 and the expression of p21(WAF1), a target protein of p53, which were induced by X-irradiation, were also suppressed by adding edaravone. We conclude that the free radical scavenger edaravone suppresses X-ray-induced apoptosis in MOLT-4 cells by inhibiting p53.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965547     DOI: 10.1269/jrr.07061

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  6 in total

1.  The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.

Authors:  Jianxun Han; Ivy Ma; Michael J Hendzel; Joan Allalunis-Turner
Journal:  Breast Cancer Res       Date:  2009-08-06       Impact factor: 6.466

2.  Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review).

Authors:  Kiyoshi Kikuchi; Nobuyuki Takeshige; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Chiemi Kikuchi; Narumi Iida; Hisaaki Uchikado; Naohisa Miyagi; Naoto Shiomi; Terukazu Kuramoto; Ikuro Maruyama; Motohiro Morioka; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-09-20       Impact factor: 2.447

3.  Survivin is involved in the anti-apoptotic effect of edaravone in PC12 cells.

Authors:  Xue-Yuan Liu; Ling-Ling Yao; Yu-Juan Chen; Bei-Bei Tao; Yong-Chun Yu; Wei-Hong Bian; Jing Yu; Yong-Gang Wang
Journal:  Mol Cell Biochem       Date:  2009-02-18       Impact factor: 3.396

Review 4.  Molecular Hydrogen as a Potential Clinically Applicable Radioprotective Agent.

Authors:  Shin-Ichi Hirano; Yusuke Ichikawa; Bunpei Sato; Haru Yamamoto; Yoshiyasu Takefuji; Fumitake Satoh
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

5.  Oxidative stress due to radiation in CD34(+) hematopoietic progenitor cells: protection by IGF-1.

Authors:  Konstantina Floratou; Efstathia Giannopoulou; Anna Antonacopoulou; Marina Karakantza; George Adonakis; Dimitrios Kardamakis; Panagiota Matsouka
Journal:  J Radiat Res       Date:  2012-07-10       Impact factor: 2.724

6.  Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA.

Authors:  Kuniki Hata; Ayumi Urushibara; Shinichi Yamashita; Mingzhang Lin; Yusa Muroya; Naoya Shikazono; Akinari Yokoya; Haiying Fu; Yosuke Katsumura
Journal:  J Radiat Res       Date:  2014-09-11       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.